# US 2016/0251376 A1 · Tyk2 inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251376 A1
- Document ID: US20160251376A1
- Status: Published application
- Kind: A1
- Application number: 15/054,594
- Filed: 2016-02-26
- Published: 2016-09-01
- Earliest claimed: 2015-02-27
- Assignees: Nimbus Lakshmi, Inc.
- Applicants: Nimbus Lakshmi, Inc.
- Inventors: Markus Dahlgren; Jeremy Robert Greenwood; Geraldine C. Harriman; Joshua Jahmil Kennedy-Smith; Craig E. Masse; Donna L. Romero; Mee Shelley; Ronald T. Wester
- Web page: https://patentgrep.com/patent/US20160251376A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07F 5/025: {Boronic and borinic acid compounds}
- C07F 5/027: {Organoboranes and organoborohydrides}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3

A compound of formula III:
or a pharmaceutically acceptable salt thereof, wherein:
each of X and Y is independently ═C(R6)—, ═N—, or ═N+(→O−)—, provided that X and Y are not simultaneously ═C(R6)—;
Ring A is phenyl; a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-6 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 4-6 membered saturated or partially unsaturated carbocyclic ring; wherein Ring A is substituted with m instances of R7;
each of R1 and R1′ is independently hydrogen, —R2, halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, or —N(R)S(O)2R; or
R1 and R1′ are taken together to form an oxo group or with their intervening atoms to form an optionally substituted 3-7 membered spiro-fused ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each R2 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R3 is a group selected from C1-6 alkyl, phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R3 is substituted with n instances of R8;
R4′ and one instance of R7 are taken together with their intervening atoms to form a 5-6 membered partially unsaturated or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
R5 is a group selected from halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)S(O)2R, phenyl, a 3-14 membered saturated or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R5 is substituted with p instances of R9;
R6 is hydrogen, —R2, halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, or —N(R)S(O)2R;
each instance of R7, R8, R10, and R11 is independently oxo, —R2, halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, or —N(R)S(O)2R;
each instance of R9 is independently oxo, C1-6 hydroxyaliphatic, —R2, halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, or —N(R)S(O)2R;
L1 is a covalent bond or a C1-6 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by C(R10)2—, —N(R)—, —N(R)C(O)—, —C(O)N(R)—, —N(R)S(O)2—, —S(O)2N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)— or S(O)2—; or
L1 and one instance of R7 are taken together with their intervening atoms to form a 5-10 membered partially unsaturated or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulfur, and boron; wherein said ring is substituted by q instances of R11; and R5 is attached to any position of the ring formed by L1 and R7;
m is 0-4;
n is 0-4;
p is 0-6;
q is 0-4; and
each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

### Claim 4

(canceled)

### Claim 5 (depends on 3)

The compound of claim 3 wherein Ring A is phenyl, pyridin-2-yl, pyridine-3-yl, or pyrazol-4-yl.

### Claim 6

(canceled)

### Claim 7 (depends on 3)

The compound of claim 3 wherein X is ═C(R6)—; and Y is ═N—.

### Claim 8 (depends on 3)

The compound of claim 3 wherein R6 is hydrogen.

### Claim 9 (depends on 3)

The compound of claim 3 wherein L1 is CH2C(O)—, —C(O)—, or a covalent bond.

### Claim 10 (depends on 9)

The compound of claim 9, wherein L1 is —C(O)—.

### Claim 11 (depends on 9)

The compound of claim 9, wherein L1 is a covalent bond.

### Claim 12 (depends on 3)

The compound of claim 3 wherein R3 is phenyl, pyrrolidinyl, or piperidinyl.

### Claim 13 (depends on 3)

The compound of claim 3 wherein R3 is phenyl.

### Claim 14 (depends on 3)

The compound of claim 3 wherein n is 2, and at least one R8 is fluoro.

### Claim 15

A compound selected from those depicted in Table 1 of the specification, or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 3)

A pharmaceutical composition comprising a compound according to claim 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 17 (depends on 3)

A method of inhibiting TYK2 in a biological sample comprising contacting the sample with the compound of claim 3, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 16)

A method of treating an TYK2-mediated disorder, disease, or condition in a patient comprising administering to said patient the pharmaceutical composition of claim 16.

### Claim 19 (depends on 18)

The method of claim 18 wherein the disorder is selected from an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

### Claim 20 (depends on 19)

The method of claim 19 wherein the disorder is an autoimmune disorder.

### Claim 21

(canceled)

### Claim 22 (depends on 19)

The method of claim 19 wherein the disorder is an inflammatory disorder.

### Claim 23

(canceled)

### Claim 24 (depends on 19)

The method of claim 19 wherein the disorder is a proliferative disorder.

### Claim at position 24

25-29. (canceled)

### Claim 30 (depends on 19)

The method of claim 19 wherein the disorder is associated with transplantation.

### Claim 31

(canceled)

### Claim 32 (depends on 19)

The method of claim 19 wherein the disorder is an endocrine disorder.

### Claim at position 28

33-36. (canceled)
